ReviewCurrent psychiatry reports2010
Biomarkers to predict antidepressant response.
Review in Current psychiatry reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.Molecular psychiatry · 2022Pooled it
- Pooled it
- A comparison between rTMS and antidepressant medication on depressive symptom clusters in treatment-resistant depression.European archives of psychiatry and clinical neuroscience · 2025Trial
- Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.Translational psychiatry · 2025Trial
- Investigating the relationship between hippocampus/dentate gyrus volume and hypothalamus metabolism in participants with major depressive disorder.Scientific reports · 2024Trial
- The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.BMC psychiatry · 2016Trial
- Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.The Journal of clinical psychiatry · 2012Trial
- Effect of obstructive sleep apnea on response to cognitive behavior therapy for depression after an acute myocardial infarction.Journal of psychosomatic research · 2012Trial
- Baseline mood-state measures as predictors of antidepressant response to scopolamine.Psychiatry research · 2012Trial
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- Distinct genetic responses to fluoxetine sertraline and citalopram in mouse cortical neurons.iScience · 2025Article
- Cross-EHR validation of antidepressant response algorithm and links with genetics of psychiatric traits.medRxiv : the preprint server for health sciences · 2024Article
- Are There Biological Correlates of Response to Yoga-Based Interventions in Depression? A Critical Scoping Review.Brain sciences · 2024Article
- One size does not fit all: notable individual variation in brain activity correlates of antidepressant treatment response.Frontiers in psychiatry · 2024Article
- Article
- Circadian rhythm biomarker from wearable device data is related to concurrent antidepressant treatment response.NPJ digital medicine · 2023Article
- Model-interpreted outcomes of artificial neural networks classifying immune biomarkers associated with severe infections in ICU.Frontiers in immunology · 2023Article
- Article
- Bibliometric Analysis of Quantitative Electroencephalogram Research in Neuropsychiatric Disorders From 2000 to 2021.Frontiers in psychiatry · 2022Article
- Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder.General psychiatry · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past several years, we have achieved a deeper understanding of the etiology/pathophysiology of major depressive disorder (MDD). However, this improved understanding has not translated to improved treatment outcome. Treatment often results in symptomatic improvement, but not full recovery. Clinical approaches are largely trial-and-error, and when the first treatment does not result in recovery for the patient, there is little proven scientific basis for choosing the next. One approach to enhancing treatment outcomes in MDD has been the use of standardized sequential treatment algorithms and measurement-based care. Such treatment algorithms stand in contrast to the personalized medicine approach, in which biomarkers would guide decision making. Incorporation of biomarker measurements into treatment algorithms could speed recovery from MDD by shortening or eliminating lengthy and ineffective trials. Recent research results suggest several classes of physiologic biomarkers may be useful for predicting response. These include brain structural or functional findings, as well as genomic, proteomic, and metabolomic measures. Recent data indicate that such measures, at baseline or early in the course of treatment, may constitute useful predictors of treatment outcome. Once such biomarkers are validated, they could form the basis of new paradigms for antidepressant treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.